ENPREVIT[®] VITAMIN.

(VITAMIN A, VITAMIN B-COMPLEX AND GINSENG TABLETS)

SUBMITTED BY: NALIS PHARMACEUTICALS LTD

R67-68 NEKEDE-NAZE INDUSTRIAL CLUSTERS, NEKEDE, OWERRI, IMO STATE, NIGERIA. TEL: +2348085784400, +2349026044603

Email: info@nalispharma.com, www.nalispharma.com

SUMMARY OF PRODUCT CHARACTERISTICS

(SmPC).

NAME OF THE DRUG PRODUCT 1.

Enprevit[®] Vitamin Tablet

QUALITATIVE AND QUANTITATIVE COMPOSITION 2.

Each tablet contains:

Vitamin A Acetate B.P.	2000 IU
Vitamin B ₃ B.P	200 IU
Vitamin B ₁ (Thiamine HCI) B.P	1 mg
Vitamin B ₂ (Riboflavin) B.P	1 mg
Vitamin B ₆ (Pyridoxine) B.P	.5 mg
Niacinamide BP	15 mg
Ginseng	990mcg
Excipients	q.s

CLINICAL PARTICULARS 4

4.1 Therapeutic indications

Oral prophylactic and therapeutic treatment of vitamins A and B-complex deficiencies. Enprevit is also indicated for healthy body, growth, good appetite, convalescence, and all conditions where there is need to withstand stress and increased demands.

4.2 Posology and method of administration

Prophylactic

Adults and children over 12 years

One tablet daily

Or as prescribed by a physician

4.3 Contradindications

Known sensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

No special warnings.

4.5 Interaction with other drug products and other forms of interaction The pyridoxine hydrochloride may reduce the effectiveness of levodopa.

4.6 Fertility, pregnancy and lactation

Considered safe in the recommended dose.

4.7 Effects on ability to drive and use machines

None stated

4.8 Undesirable effects

None known

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the regulatory bodies such as NAFDAC.

4.9 Overdose

Not applicable

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Vitamin A Acetate Vitamin A is required for growth and bone development, vision, reproduction and the integrity of mucosal and epithelial surfaces. In the retina, retinol is converted to the aldehyde, cis-retinal, which combines with opsin to form rhodopsin, the visual pigment.

Vitamin B Complex.

Niacin (Vit B₃): Niacin can decrease lipids and apolipoprotein B (apo B)-containing lipoproteins by modulating triglyceride synthesis in the liver, which degrades apo B, or by modulating lipolysis in adipose tissue. Niacin inhibits hepatocyte diacylglycerol acyltransferase-2.

Thiamine Hydrochloride (Vit B1): A water soluble vitamin. It is a co-enzyme for carbohydrate metabo

Riboflavin Sodium Phosphate (Vit B2): A water soluble vitamin converted in the body to flavine mononucleotide and flavine adenine dinucleotide and then involved as co-enzymes in oxidative and reductive meta nroces

Niacinamide: A water soluble vitamin considered part of the Vitamin B group. Converted to Nicotinamide Adenine Dinucleotide and Nicotinamide Adenine Dinucleotide Phosphate in the body, both of which are co-enzymes important in electron transfer in respiratory reactions.

Pyridoxine Hydrochloride (Vit B4): A water soluble vitamin. Involved in carbohydrate and fat metabolism, but also important in haemoglobin formation.

Ginseng It is commonly believed that most pharmacological effects of P. ginseng are attributed to ginsenosides, including the stimulatory and inhibitory effects on the nervous system, antineoplastic effects, immunomodulatory effects, and nitric oxide release.

5.2 Pharmacokinetic properties

The B-complex vitamins are water soluble vitamins. Quantities in excess of the bodies requirements are excreted either unchanged or as metabolites, mainly in the urine but to a lesser extent also in the faces.

Newly absorbed vitamin A is stored in the liver as retinyl esters. Storage involves both the hepatic parenchymal cells and the nonparenchymal stellate cells. Vitamin A is mobilized from liver stores and transported in plasma as retinol bound to a specific transport protein, retinol-binding protein.

After oral ingestion, ginsenoside metabolites are absorbed from the gut into systemic circulation.

5.3 Preclinical safety data

None stated

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Methyl paraben, propyl paraben, corn starch, lactose

BP: British Pharmacopoeia

6.2 Incompatibilities

None known

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store between 4°C and 25°C. Protect from light.

6.5 Nature and contents of container

PVC blisters and aluminium foil.

6.6 Special precautions for disposal of used medicinal product or waste materials derived from such medicinal product and other handling of the product

None stated

7. APPLICANT/HOLDER OF CERTIFICATE OF PRODUCT REGISTRATION

NAME: NALIS PHARMACEUTICALS LTD

ADDRESS:

R67-68 Nekede-Naze Industrial Clusters, Nekede, Owerri, IMO State, Nigeria. Tel: +2348085784400, +2349026044603

Email: info@nalispharma.com, www.nalispharma.com

8. DRUG PRODUCT MANUFACTURER

NAME: NALIS PHARMACEUTICALS LTD

ADDRESS:

R67-68 Nekede-Naze Industrial Clusters, Nekede, Owerri, IMO State, Nigeria. Tel: +2348085784400, +2349026044603

Email: info@nalispharma.com, www.nalispharma.com

9. NAFDAC REGISTRATION NUMBER(S):

A11-100476